The Cheapest Legitimate Way to Get Semaglutide in 2026
Released · Last reviewed
If insured, a covered Wegovy copay (~$25/mo) is cheapest. Uninsured, compounded semaglutide from ~$119/mo usually beats brand self-pay (~$349 NovoCare), but is not FDA-approved.
- Insured Wegovy copay can be ~$25/mo — beats every cash option.
- Uninsured, compounded from ~$145/mo is usually cheapest but not FDA-approved.
- Brand self-pay via NovoCare (~$349/mo) buys the approved product and trial evidence.
- Watch required memberships and intro-only pricing that inflate real cost.
If you have insurance
The cheapest legitimate route for many patients is an insured brand prescription. When a commercial plan covers Wegovy for weight management, the copay can be as low as about $25 per month with a manufacturer savings card, which undercuts every cash-pay compounded option by an order of magnitude and comes with FDA-approved medication.
The catch is coverage. Most plans require a documented obesity diagnosis and often prior authorization, and Medicare does not cover GLP-1s for weight loss under current law. Employer plans vary widely, with roughly a third to half covering weight-management GLP-1s in 2026.
Price your insured copay first, because if it exists, nothing else competes. Call the number on your insurance card and ask specifically about the weight-loss indication and prior-authorization requirements.
If you are paying cash
Uninsured, compounded semaglutide is usually the cheapest path, with a median of $99 a month across the 22 programs we priced on October 15, 2026. It is not FDA-approved, which is the fundamental trade-off.
Brand self-pay through NovoCare runs about $349 per month for Wegovy, which is more expensive but delivers the FDA-approved product with full trial backing. The oral Wegovy tablet is available from about $149 per month for qualifying patients, competitive with compounded for people who prefer a pill and an approved product.
Between these poles, telehealth compounded programs cluster from $145 to $299 depending on required fees and commitment. The spread is wide, so comparison matters.
| Route | Typical monthly | FDA-approved? | Best for |
|---|---|---|---|
| Insured Wegovy copay | ~$25 (if covered) | Yes | Anyone with coverage |
| Compounded semaglutide | $145–299 | No | Uninsured, cost-first |
| Oral Wegovy (NovoCare) | from $149 | Yes | Pill preference, qualifying patients |
| Brand Wegovy self-pay | ~$349 | Yes | Uninsured wanting approved product |
The pricing traps to avoid
Two traps inflate the real cost. First, the required membership: a program advertising $99 medication plus a mandatory $79 membership is really $178. Second, the intro rate: a $99 first month that reverts to $299 on refill is not a $99 program.
Compare renewal price and effective monthly cost, not the headline. A program that looks cheapest at signup can be the most expensive by month three.
Also avoid sub-market pricing that seems too good to be true. A legitimate compounded program has real pharmacy and clinician costs; pricing far below the market floor is a red flag for sourcing or safety problems.
Cheapest routes, ranked
For an insured patient with coverage, the ranking is clear: insured brand copay first, then compounded cash, then brand self-pay. For a cash-pay patient, compounded semaglutide usually wins on price, with brand self-pay as the FDA-approved alternative if the lack of approval concerns you.
The table and chart below lay out the routes by typical monthly cost. Remember that the cheapest route is not automatically the best: an approved product with trial evidence has value that a price tag alone does not capture.
Your clinician determines which route is appropriate for your history and goals.
| Program type | Headline | Real effective/mo |
|---|---|---|
| Membership program | $99 | $178 (+$79 membership) |
| Intro-rate program | $99 first mo | $299 renewal |
| Flat bundled program | $145 | $145 |
The bottom line
The genuinely cheapest legitimate semaglutide depends on your insurance. Covered, the copay wins. Uninsured, compounded is usually cheapest, with brand self-pay as the approved alternative.
Whichever route you choose, confirm the pharmacy is named and state-licensed, compare renewal not intro pricing, and include every mandatory fee in your comparison.
Compounded semaglutide is not FDA-approved and requires a prescription after a clinician evaluation.
Frequently asked questions
What is genuinely the cheapest way?
An insured Wegovy copay if you have coverage (as low as ~$25/mo). Without insurance, compounded semaglutide from ~$119/mo is usually cheapest but not FDA-approved.
Is compounded semaglutide safe and legal?
It is legal in limited patient-specific circumstances and dispensed by licensed pharmacies, but it is not FDA-approved and carries no formulation-specific trial evidence. Verify the pharmacy first.
Does Medicare cover semaglutide for weight loss?
Not under current law for weight loss alone. Medicare covers semaglutide products like Ozempic for type 2 diabetes.
How do I avoid the intro-rate trap?
Ask for the renewal price, not the first-month price, and compare providers on that number.
Sources
- FDA — human drug compounding and GLP-1 status.
- Provider pricing pages and manufacturer sources, captured September 2026.
- Forbes Health and U.S. News & World Report provider reviews, captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $49 to $279 a month across the 22 programmes we priced on October 15, 2026, with a median of $99. The spread is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $87 and Eden at $99; lower stickers come with a sale, a prepaid year or a membership. Half the programmes sit below $99 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Two programmes printed a semaglutide microdose price on October 15, 2026 (Shed from $149, Noom Med $179); NexLife's microdose semaglutide has cost the same as its standard plan since November 8, 2026 ($109 a month month-to-month). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Checking the figures in semaglutide
On October 15, 2026, compounded semaglutide ran $49 to $279 a month across the 22 programmes we priced. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Standard-dose semaglutide spans $49 to $279 a month across the 22 programmes we priced on October 15, 2026, a spread of $230.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
What does compounded semaglutide cost per month in October 2026?
As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.
What does compounded semaglutide normally cost?
$49 to $279 a month at the lowest all-in rate across the 22 programs we priced on October 15, 2026, with a median of $99. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. On October 15, 2026, Shed listed a semaglutide microdose from $149 a month and Noom Med at $179 after a $79 start. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.